Entrada Ventures fund aims to help grow technology startups
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen partners with Institute for Protein Design
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen joins lawsuit to block rule requiring drug pricing in TV ads
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Cure Pharmaceuticals may double shares of common stock
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →FDA approves Amgen biosimilar Kanjinti
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Serimmune issues $1.4 million in promissory notes
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Sienna, MannKind stocks move on new trial data
Two Westlake Village biotech companies released new data from product trials, spurring stock moves and presaging capital raises to fund further research and development. Analysts remained optimistic on Sienna Biopharmaceuticals despite an 18 percent drop in the stock June 10, after the company released results from clinical trials of its psoriasis product. Despite the Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
